IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1264.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 8-Apr-2014
JAMA
Chemotherapy may be better for certain patients with advanced lung cancer
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene, conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Contact: Dong-Wan Kim
kimdw@snu.ac.kr
The JAMA Network Journals

Public Release: 8-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Study examines biomarkers in HPV negative squamous-cell carcinomas of the head and neck
A quartet of proteins that play critical roles in cell replication, cell death and DNA repair could lead to better targets for therapy against treatment-resistant head-and-neck squamous cell cancers.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 8-Apr-2014
Health Affairs
Global health funding reaches new high as funding priorities shift
Global health funding hit an all-time high of $31.3 billion in 2013, five times greater than in 1990. Yet with 3.9 percent growth from 2012 to 2013, the year-over-year increase falls short of the rapid rates seen over the previous decade, according to new research by the Institute for Health Metrics and Evaluation at the University of Washington being published online in a web first edition on Apr. 8 by Health Affairs.

Contact: Rhonda Stewart
stewartr@uw.edu
206-897-2863
Institute for Health Metrics and Evaluation

Public Release: 8-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Phase II trial of efatutazone shows challenge of matching treatment to population
Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported today at the American Association for Cancer Research Annual Meeting 2014. While efatutazone did not improve the efficacy of erlotinib in this trial, researchers hope lessons from the trial will allow them to make better future use of the drug or other drugs in its class.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 8-Apr-2014
Lancet Oncology
Unexpected results in cancer drug trial
Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.
Cancer Research UK

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton

Public Release: 8-Apr-2014
Journal of Experimental Medicine
Montreal researchers explain how our immune system kills abnormal blood cells
A team of researchers at the IRCM, led by Andre Veillette, M.D., explains how our immune system kills abnormal blood cells. Their discovery, recently published in the Journal of Experimental Medicine, could eventually lead to new treatment avenues for leukemia, lymphoma and certain types of infectious viral diseases.
Canadian Institutes of Health Research, Canadian Cancer Society Research Institute, Canada Research Chairs

Contact: Julie Langelier
julie.langelier@ircm.qc.ca
514-987-5555
Institut de recherches cliniques de Montreal

Public Release: 8-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Fox Chase study identifies the process in which heat shock protein 90 contributes to metastases in ovarian cancer
By incapacitating the activities of a protein that guides other proteins to fold into a stable shapes, Fox Chase Cancer Center researchers shut off the spigot for two proteases that help ovarian cancer cells chew their way out of the tissue they grow in and dig in at new locations.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 8-Apr-2014
Applied and Environmental Microbiology
Western University study unlocking secrets of breast tissue
A unique population of microbes in the female breast may lay the groundwork for understanding how this bacterial community contributes to health and disease, according to a new study out of Western University. Forms of bacteria known as 'Proteobacteria' were the most abundant, potentially as they are able to metabolize the fatty tissue, said the paper's first author, Camilla Urbaniak, a Ph.D. student.

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario

Public Release: 8-Apr-2014
Nature
Breast cancer cell subpopulation cooperation can spur tumor growth
Sub-populations of breast cancer cells sometimes cooperate to aid tumor growth, according to Penn State College of Medicine researchers, who believe that understanding the relationship between cancer sub-populations could lead to new targets for cancer treatment.
NIH/National Cancer Institute, Mary Kay Foundation

Contact: Matthew Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State

Public Release: 8-Apr-2014
Biostatistics
New epidemiology model combines multiple genomic data
Data about DNA differences, gene expression, or methylation can each tell epidemiologists something about the link between genomics and disease. A new statistical model that can integrate all those sources provides a markedly improved analysis, according to two new papers.
National Institutes of Health, Brown University

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University

Public Release: 8-Apr-2014
Few Americans know where elected officials and candidates stand on government support for research
Two-thirds of Americans (66 percent) say it's important for candidates running for office to assign a high priority to funding medical research, according to America Speaks, Volume 14, a compilation of key questions from public opinion polls commissioned by Research!America. Polling shows that Americans place a high value on US leadership in medical innovation, yet only 12 percent say they are very well informed about the positions of their senators and representative when it comes to their support of medical and scientific research.

Contact: Anna Briseno
abriseno@researchamerica.org
571-482-2737
Research!America

Public Release: 8-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Dartmouth researchers identify potential therapeutic target for deadly brain cancer
Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014, at the American Association of Cancer Researchers conference in San Diego, Calif. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Public Release: 7-Apr-2014
Nature Immunology
La Jolla Institute discovers new mechanism for unleashing immune system against cancer
A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.
National Institutes of Health

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Studies reveal more clues on how pregnancy protects against breast cancer
Scientists at Fox Chase Cancer Center have unearthed new clues about how pregnancy reduces women's risk of developing breast cancer. The research will be presented at the American Association for Cancer Research Annual Meeting 2014.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Milk thistle extract, silibinin, reduces self-renewal of colorectal cancer stem cells
A University of Colorado Cancer Center study presented today at the American Association for Cancer Research Annual Meeting 2014 shows that the chemical silibinin, purified from milk thistle extract, affects cell signaling associated with inflammation and thus also the formation and survival of colorectal cancer stem cells.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Gold nanorods attach to, kill bladder cancer cells
A University of Colorado Cancer Center study presented today at the American Association for Cancer Research Annual Meeting 2014 demonstrates a novel strategy that accomplishes both: bladder cancer cells overexpress the protein EGFR; gold nanorods can be engineered to attach to EGFR proteins; and then the application of low-intensity laser to the tissue can preferentially heat these gold nanorods, killing the EGFR-rich cancer cells to which they are attached.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Research yields potential target for epithelial ovarian cancer treatment
Fox Chase Cancer Center researchers who are investigating the biological mechanisms behind metastatic epithelial ovarian cancer recently found that an enzyme called focal adhesive kinase can play a critical -- and previously unstudied -- role in the growth and spread of the disease. The research will be presented on Monday, April 7, at the American Association for Cancer Research Annual Meeting 2014.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Proceedings of the National Academy of Sciences
For good and ill, immune response to cancer cuts both ways
The difference between an immune response that kills cancer cells and one that conversely stimulates tumor growth can be as narrow as a 'double-edged sword,' report researchers at the University of California San Diego School of Medicine in the April 7, 2014, online issue of the Proceedings of the National Academy of Sciences.
Samuel and Ruth Engelberg Fellowship at the Cancer Research Institute

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
New breast cancer results illustrate promise and potential of I-SPY 2 trial
In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco

Public Release: 7-Apr-2014
Surgery
Tissue testing during breast cancer lumpectomies
Unique laboratory testing during breast cancer lumpectomies to make sure surgeons remove all cancerous tissue spares patients the need for a repeat lumpectomy in roughly 96 percent of cases at Mayo Clinic in Rochester, a success rate much higher than the rate nationally, a Mayo study shows.
Mayo Clinic

Contact: Sharon Theimer
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 7-Apr-2014
Proceedings of the National Academy of Sciences
Well-known cancer gene NRAS produces 5 variants, study finds
A new study shows that the NRAS gene, known to play a fundamental role in cancer development, produces five gene variants, or isoforms, rather than just one form, as thought. The study identified four previously unknown variants that the NRAS gene produces. The finding might help improve drugs for cancers in which NRAS plays a crucial role. It also suggests that NRAS might affect additional target molecules in cells.
NIH/National Cancer Institute, Coleman Leukemia Research Foundation, Pelotonia Fellowship Program

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 7-Apr-2014
European Urology
Henry Ford Hospital cited: World's first surgical innovators for patient safety standards
An innovative kidney transplant technique developed by Henry Ford Hospital is credited as the first in the world to use a new set of patient safety standards coordinated by the University of Oxford in England. The standards are being assembled and offered as a framework for developing, performing and reporting surgical innovations that, unlike new medical treatments, are not under strict regulations and control.

Contact: Dwight Angell
dwight.angell@hfhs.org
313-850-3471
Henry Ford Health System

Public Release: 7-Apr-2014
American Association for Cancer Research (AACR) Annual Meeting 2014
Disruption of VISTA plays an important role in regulating immune response
Researchers at the Geisel School of Medicine at Dartmouth have found that the body's immune system response was enhanced when they disrupted VISTA, a protein that prevents the immune system from overreacting. Understanding how checkpoint regulators like VISTA function is important to cancer researchers, who hope to use the immune system to attack tumors.
National Institutes of Health, Hitchcock Foundation, Melanoma Research Foundation, Wellcome Trust, Medical Research Council Centre for Transplantation and Biomedical Research Center at King's College London

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Public Release: 7-Apr-2014
Nature Communications
Novel plant biotechnology approach for sustainable production of pharmaceutical compounds
European scientists have made ground-breaking discoveries for improving the efficiency of the production of pharmaceuticals through plant biotechnology.
European Commission

Contact: Dr. Kirsi-Marja Oksman-Caldentey
kirsi-marja.oksman@vtt.fi
358-207-224-459
VTT Technical Research Centre of Finland

Public Release: 7-Apr-2014
29th Annual EAU Congress
New method for prostate cancer detection can save millions of men painful examination
Each year prostate tissue samples are taken from over a million men -- in most cases using 12 large biopsy needles -- to check whether they have prostate cancer. This procedure, which was recently described by an American urology professor as 'barbaric,' shows that 70 percent of the subjects do not have cancer. A patient-friendly examination, which drastically reduces the need for biopsies has been developed at Eindhoven University of Technology, together with AMC Amsterdam.
European Research Council, KWF Dutch Cancer Foundation, Netherlands Organisation for Scientific Research

Contact: Massimo Mischi
m.mischi@tue.nl
31-613-269-039
Eindhoven University of Technology

Showing releases 1076-1100 out of 1264.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!